Last updated on August 2018

The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Polycythemia Vera
  • Age: Between 18 - 60 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age 18-60 years
  • Diagnosis of Polycythemia Vera according to World Health Organization 2016 criteria
  • Diagnosis of Polycythemia Vera performed within 3 years prior inclusion in the study and never treated with cytoreductive drugs
  • HCT<45%
  • Ability and willingness to comply with all study requirements
  • Signed written informed consent.

Exclusion Criteria:

  • Any previous well documented cardiovascular PV-related events (see Appendix 1 for description)
  • Previous cytoreductive drugs
  • Known hypersensitivity or contraindications to the Investigational Medicinal Product (Pegylated Proline-Interferon alpha-2b) including:

evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension); thyroid dysfunction not adequately controlled; patients tested positively with Thyroglobulin antibody and / or TPOAb at screening; documented autoimmune disease at screening or in the medical history; history or presence of depression requiring treatment with antidepressant; any risk of suicide at screening or previous suicide attempts;

  • Previous exposure to a non-pegylated or pegylated interferon
  • Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis
  • Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening
  • Significant liver (AST or alanine aminotransferase > 2.5 times ULN) or renal disease (creatinine > 2 mg/ml)
  • Presence of any life-threatening condition or of any disease (e.g. cancer) that is likely to significantly shorten life expectancy
  • History of active substance or alcohol abuse within the last year
  • Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol
  • Pregnant or lactating women and women*/men of childbearing potential who are not using or are not willing to use any effective means of contraception (i.e. sexual abstinence, hormonal contraceptive, intra-uterine device, barrier method such as diaphragms or condoms, surgical methods).
  • Pregnancy test will be performed in order to ascertain negativity of human chorionic gonadotropin (-hCG) test and confirm that childbearing women are not pregnant.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.